Superinfections in patients treated with Teicoplanin as anti-SARSCoV2 agent

Eur J Clin Invest. 2020 Sep 30:e13418. doi: 10.1111/eci.13418. Online ahead of print.


We read with interest the paper by Giacobbe et al. estimating a cumulative risk of developing at least one bloodstream infection (BSI) episode (largely due to Gram-positive pathogens) of almost 50% after 30 days at risk in severe COVID-19 patients. (2) Similarly, Somers et al. reported an increased risk to develop bacterial superinfections, principally represented by Staphylococcus aureus ventilatory associated pneumonia (VAP), in critically ill patients infected with SARS-CoV-2 and treated with Tocilizumab.

PMID:32997792 | DOI:10.1111/eci.13418